Cargando…
Peripheral CD8+CD28+ T lymphocytes predict the efficacy and safety of PD-1/PD-L1 inhibitors in cancer patients
BACKGROUND: Programmed cell death protein-1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitors works by reactivating immune cells. Considering the accessibility of noninvasive liquid biopsies, it is advisable to employ peripheral blood lymphocyte subsets to predict immunotherapy outcomes. METHOD...
Autores principales: | Geng, Ruixuan, Tang, Hui, You, Tingting, Xu, Xiuxiu, Li, Sijian, Li, Zepeng, Liu, Yuan, Qiu, Wei, Zhou, Na, Li, Ningning, Ge, Yuping, Guo, Fuping, Sun, Yuhong, Wang, Yingyi, Li, Taisheng, Bai, Chunmei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10038730/ https://www.ncbi.nlm.nih.gov/pubmed/36969245 http://dx.doi.org/10.3389/fimmu.2023.1125876 |
Ejemplares similares
-
Safety and Efficacy of PD-1/PD-L1 Inhibitors in Cancer Patients With Preexisting Autoantibodies
por: Tang, Hui, et al.
Publicado: (2022) -
Anti-PD-1 Therapy Response Predicted by the Combination of Exosomal PD-L1 and CD28
por: Zhang, Chaoxu, et al.
Publicado: (2020) -
Triggering of lymphocytes by CD28, 4-1BB, and PD-1 checkpoints to enhance the immune response capacities
por: Kaviani, Elina, et al.
Publicado: (2022) -
PD1 functions by inhibiting CD28-mediated co-stimulation
por: O'Donnell, Jake S, et al.
Publicado: (2017) -
Accumulation of CD5(+)CD19(+) B lymphocytes expressing PD-1 and PD-1L in hypertrophied pharyngeal tonsils
por: Wlasiuk, Paulina, et al.
Publicado: (2015)